
|Videos|September 9, 2021
Should anti-VEGF agents be used to treat NPDR patients?
Jennifer Sun, MD, MPH, explores the question of whether ophthalmologists should be using anti-VEGF agents to treat patients with nonproliferative diabetic retinopathy (NPDR).
Advertisement
Jennifer Sun, MD, MPH, associate professor of Ophthalmology, Harvard Medical School; chief at the Center for Clinical Eye Research and Trials, Joslin Diabetes Center, explores the question of whether ophthalmologists should be using anti-VEGF agents to treat patients with nonproliferative diabetic retinopathy (NPDR).
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Metformin use associated with reduced incidence of intermediate AMD
2
MeiraGTx Licenses complement-targeted geographic atrophy program from ZipBio
3
Looking back at the 2025 EnVision Summit
4
Last year in glaucoma at EnVision Summit 2025
5




























